[HTML][HTML] NF-κB inhibitors in treatment and prevention of lung cancer
RR Rasmi, KM Sakthivel… - Biomedicine & …, 2020 - Elsevier
Intracellular signalling pathways have provided excellent resource for drug development
particularly in the development of cancer therapeutics. A wide variety of malignancies …
particularly in the development of cancer therapeutics. A wide variety of malignancies …
The quest to overcome resistance to EGFR-targeted therapies in cancer
CR Chong, PA Jänne - Nature medicine, 2013 - nature.com
All patients with metastatic lung, colorectal, pancreatic or head and neck cancers who
initially benefit from epidermal growth factor receptor (EGFR)-targeted therapies eventually …
initially benefit from epidermal growth factor receptor (EGFR)-targeted therapies eventually …
The NF-κB activation pathways, emerging molecular targets for cancer prevention and therapy
Y Lin, L Bai, W Chen, S Xu - Expert opinion on therapeutic targets, 2010 - Taylor & Francis
Importance of the field: Nuclear factor kappa B (NF-κB) is activated by a variety of cancer-
promoting agents. The reciprocal activation between NF-κB and inflammatory cytokines …
promoting agents. The reciprocal activation between NF-κB and inflammatory cytokines …
Effect of sulindac and erlotinib vs placebo on duodenal neoplasia in familial adenomatous polyposis: a randomized clinical trial
NJ Samadder, DW Neklason, KM Boucher, KR Byrne… - Jama, 2016 - jamanetwork.com
Importance Patients with familial adenomatous polyposis (FAP) are at markedly increased
risk for duodenal polyps and cancer. Surgical and endoscopic management of duodenal …
risk for duodenal polyps and cancer. Surgical and endoscopic management of duodenal …
[PDF][PDF] NF-kappaB in lung cancer, a carcinogenesis mediator and a prevention and therapy target
W Chen, Z Li, L Bai, Y Lin - Front Biosci (Landmark Ed), 2011 - article.imrpress.com
Introduction 3. NF-kappaB activation pathways 3.1. Protein components in the NF-kappaB
family 3.2. The pathways leading to NF-kappaB activation 4. NF-kappaB's cellular functions …
family 3.2. The pathways leading to NF-kappaB activation 4. NF-kappaB's cellular functions …
Efficacy of therapy with bortezomib in solid tumors: a review based on 32 clinical trials
Z Huang, Y Wu, X Zhou, J Xu, W Zhu, Y Shu… - Future oncology, 2014 - Taylor & Francis
The ubiquitin–proteasome system is a major pathway for protein degradation, so that
proteasome is now considered as an important target for drug discovery. Bortezomib, the …
proteasome is now considered as an important target for drug discovery. Bortezomib, the …
Association of sulindac and erlotinib vs placebo with colorectal neoplasia in familial adenomatous polyposis: secondary analysis of a randomized clinical trial
NJ Samadder, SK Kuwada, KM Boucher… - JAMA …, 2018 - jamanetwork.com
Importance Patients with familial adenomatous polyposis (FAP) are at markedly increased
risk for colorectal polyps and cancer. A combination of sulindac and erlotinib led to a 71 …
risk for colorectal polyps and cancer. A combination of sulindac and erlotinib led to a 71 …
The use of hollow mesoporous silica nanospheres to encapsulate bortezomib and improve efficacy for non-small cell lung cancer therapy
Bortezomib (BTZ) is the first clinically approved proteasome inhibitor for treating multiple
human malignancies. However, the poor water-solubility and low stability of BTZ and the …
human malignancies. However, the poor water-solubility and low stability of BTZ and the …
Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: meta-analysis of 153 cohorts with 15,713 patients: meta …
Purpose Pneumonitis is a significant toxicity of EGFR tyrosine kinase inhibitors (EGFR-TKI)
in non-small-cell lung cancer (NSCLC) patients. We studied the incidence of pneumonitis in …
in non-small-cell lung cancer (NSCLC) patients. We studied the incidence of pneumonitis in …
[HTML][HTML] KRAS mutation as a prognostic factor and predictive factor in advanced/metastatic non-small cell lung cancer: A systematic literature review and meta …
RE Goulding, M Chenoweth, GC Carter… - Cancer Treatment and …, 2020 - Elsevier
Abstract KRAS (Kirsten Rat Sarcoma) is the most common oncogenic mutation detected in
patients with non-small cell lung cancer (NSCLC). However, the role of KRAS as either a …
patients with non-small cell lung cancer (NSCLC). However, the role of KRAS as either a …